Company Research Report: Harton, Inc.

Company Overview

• Name: Harton, Inc.

• Mission: To make life-changing treatments scalable and accessible to every patient in need, setting new standards in cell therapy manufacturing.

• Founded By: Richard Terry (CEO, CTO, Founder), Evan R. Daugharthy, PhD (President, CSO, Founder), Min Cui, PhD (Founder & Managing Director, Decheng Capital)

• Key People:

• Richard Terry, CEO, CTO, Founder

• Evan R. Daugharthy, PhD, President, CSO, Founder

• Min Cui, PhD, Founder & Managing Director, Decheng Capital

• Victor Tong, Jr., Managing Director, Decheng Capital

• Advisors:

• George Church, PhD, Harvard Medical School

• Yvonne Chen, PhD, UCLA

• Dennis Flannelly, MBA, Merck

• Laura Brass, PhD, MBA, Novartis Venture Fund

• Headquarters: No information is available

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Harton is known for its innovative GMP-ready, Solid-State Bioprocessing (SSB) Platform, which empowers scalable and efficient production of life-changing cell therapies.

Products

Solid-State Bioprocessing Platform

• Description: This is the first GMP-ready platform offering full stack automation, facilitating the scalable production of cell therapies. It integrates advanced automation and sensor technologies, capable of efficiently producing therapies at every stage, from therapeutic development to commercial-scale manufacturing.

• Key Features:

• 3D Culture Technology: Mimics natural cellular environments, promoting superior growth and precise control over cellular states.

• All-in-One Cartridge: Supports all unit operations within a fully closed, single-use consumable to ensure efficiency and sterility.

• Full-Stack Automation: Seamless, hands-free operation enabling clinical-scale output.

• Real-Time Insight and Monitoring: AI integration for process optimization and comprehensive digital manufacturing records.

Solid State Bioprocessor (SSB)

• Description: A high-density bioprocessing tool that powers all bioprocessing functions within a single-use consumable, ensuring cell quality and density.

• Key Features:

• Closed Design: Reduces contamination risk, assuring high sterility.

• 3D Cellular Environment: Offers optimal growth conditions for cells.

• Clinical-Scale Output: Capable of producing billions of cells with precision suitable for commercial manufacturing.

Recent Developments

• Recent Developments: No specific recent developments are mentioned.

• New Products Launched: No information is available.

• New Features Added to Existing Products: No information is available.

• New Partnerships: No information is available.

Note: No further specific detailed recent developments or changes are mentioned in the provided data. Further information may be needed for a more comprehensive update on recent activities.

This report is based solely on the data provided and does not include additional commentary or speculation beyond the available information.